Table 2.
Janus kinase inhibitors in development for ulcerative colitis.
| Ulcerative colitis | |||||||
|---|---|---|---|---|---|---|---|
| Clinical trial no. | Start | Drug | Developer | Specificity | Type | Duration | Status |
| NCT00787202 | 2008 [10] | Tofacitinib [CP-690,550] | Pfizer | JAK1, JAK2, JAK3, TYK2 | Safety | 8 weeks | Phase 2, completed |
| NCT01465763 | 2012 [4] | Tofacitinib [CP-690,550] | Pfizer | JAK1, JAK2, JAK3, TYK2 | Induction | 8 weeks | Phase 3, completed |
| NCT01458951 | 2012 [6] | Tofacitinib [CP-690,550] | Pfizer | JAK1, JAK2, JAK3, TYK2 | Induction | 8 weeks | Phase 3, completed |
| NCT01458574 | 2012 [7] | Tofacitinib [CP-690,550] | Pfizer | JAK1, JAK2, JAK3, TYK2 | Maintenance | 52 weeks | Phase 3, completed |
| NCT01470612 | 2012 [10] | Tofacitinib [CP-690,550] | Pfizer | JAK1, JAK2, JAK3, TYK2 | Long-term | 52 weeks | Phase 3, recruiting |
| NCT02000453 | 2013 [11] | GSK2586184 | Galapagos, GSK | JAK1 | Induction | 8 weeks | Phase 1, terminated |
| NCT01959282 | 2013 [11] | JNJ-54781532 | Janssen | JAK3/JAK1 | Safety | 8 weeks | Phase 2b, completed |
| NCT02819635 | 2016 [9] | ABT-494 | AbbVie | JAK1 | Induction | 8 weeks | Phase 2, recruiting |
| NCT02819635 | 2016 [9] | ABT-494 | AbbVie | JAK1 | Maintenance | 44 weeks | Phase 2, recruiting |